Cas:779331-34-9 4-bromo-3-fluoro-N,N-dimethylbenzenesulfonamide manufacturer & supplier

Chemical Name:4-bromo-3-fluoro-N,N-dimethylbenzenesulfonamide

CAS.NO:779331-34-9

Synonyms:4-bromo-N,N-dimethyl-3-fluorobenzenesulfonamide

Molecular Formula:C₈H₉BrFNO₂S

Molecular Weight:282.13000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:45.76000

Exact Mass:280.95200

LogP:2.91930

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-bromo-N,N-dimethyl-3-fluorobenzenesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-N,N-dimethyl-3-fluorobenzenesulfonamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-N,N-dimethyl-3-fluorobenzenesulfonamide Use and application,4-bromo-N,N-dimethyl-3-fluorobenzenesulfonamide technical grade,usp/ep/jp grade.

Related News: If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such. 4-bromo-3-fluoro-N,N-dimethylbenzenesulfonamide manufacturer The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it. 4-bromo-3-fluoro-N,N-dimethylbenzenesulfonamide supplier As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. 4-bromo-3-fluoro-N,N-dimethylbenzenesulfonamide vendor As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. 4-bromo-3-fluoro-N,N-dimethylbenzenesulfonamide factory The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively).